
#50 - Frank Bedu-Addo, President and CEO at PDS Biotechnology Corporation
Join us on the latest episode! Our Guest: Frank Bedu-Addo, President and CEO at PDS Biotechnology Corporation.What you'll get out of this episode:PDS Biotechnology targets the key limitations of CAR T and cancer vaccine therapies using lipid nanoparticle-based immunotherapy.Their lead candidate, PDS0101, demonstrated over 2x improvement in survival for HPV-positive head and neck cancer.The platform technology shows consistent efficacy across multiple independent Phase 2 trials.Late-stage clinical programs focus on HPV16+ head and neck cancer, with additional trials for colorectal, prostate, and MUC1+ cancers.To Learn More About Our Guest And Their Company:Guest LinkedIn https://www.linkedin.com/in/frank-bedu-addo-4797947/Company LinkedIn https://www.linkedin.com/company/pds-biotechnology-corporation/ Website https://www.pdsbiotech.com/ Our sponsor for this episode are:Sage Growth Partners https://sage-growth.com/BioBreakthroughs is part of the Slice of Healthcare podcast network:LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/













